Glimepiride Teva Sante (Glimepiride)

Glimepiride Teva Sante is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve target glycaemic control.

• Used as monotherapy in patients with mild to moderate hyperglycaemia.
• Added to metformin or other oral agents when additional glucose lowering is required.
• May be considered in patients who have stable renal function and no history of severe hypoglycaemia.
• Prescribed as part of a comprehensive diabetes management plan that includes lifestyle modification.
• Utilised when clinicians aim for gradual reduction of HbA1c in conjunction with regular monitoring.

The safety profile of glimepiride includes a range of adverse events that are reported with varying frequency.

Common

• Low blood sugar (hypoglycaemia), especially when meals are missed.
• Nausea or abdominal discomfort.
• Headache or dizziness.
• Weight gain.

Serious

• Severe hypoglycaemia leading to loss of consciousness.
• Allergic reactions such as rash, itching, or swelling.
• Liver enzyme elevations.
• Blood disorders such as neutropenia or thrombocytopenia.

Before initiating Glimepiride Teva Sante, clinicians should evaluate several clinical factors to minimise risk.

• Assess renal and hepatic function; dose adjustment may be required in impairment.
• Review history of cardiovascular disease, as sulfonylureas can affect cardiac ischemic preconditioning.
• Avoid use in patients with known hypersensitivity to sulfonylureas.
• Monitor for signs of hypoglycaemia, particularly in the elderly or those with irregular eating patterns.
• Caution during pregnancy and lactation; the safety profile is not well established.
• Consider potential impact on driving or operating machinery if hypoglycaemia occurs.

Glimepiride can interact with other medicines, altering its glucose‑lowering effect or increasing the risk of adverse events.

Avoid

• Concurrent use with other sulfonylureas or meglitinides, which may cause additive hypoglycaemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that can raise glimepiride plasma levels.

Use with caution

• Beta‑blockers, which may mask hypoglycaemia symptoms.
• Thiazide diuretics, which can affect blood glucose control.
• ACE inhibitors or ARBs, as they may enhance hypoglycaemic risk.
• Alcohol, which can potentiate hypoglycaemia.